1. World Health Organization. Global progress report on HIV, viral hepatitis, and sexually transmitted infections. 2021. https://www.globalhep.org/sites/default/files/content/resource/files/2021-05/WHO%20Progress%20Report%202021.pdf.
2. Fabrizi F, Messa P. Treatment Choices for Hepatitis C in Patients with Kidney Disease. Clin J Am Soc Nephrol. 2018 May 7;13(5):793-795. doi: 10.2215/CJN.12621117. Epub 2018 Mar 9. PMID: 29523677; PMCID: PMC5969487.
3. Nguyen DB, Bixler D, Patel PR. Transmission of hepatitis C virus in the dialysis setting and strategies for its prevention. Semin Dial. 2019;32(2):127-34.
4. Brunner N, Bruggmann P. Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination. J Prev Med Public Health. 2021;54(4):251-8.
5. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med. 2017;166(9):637-48.
6. Chen YC, Li CY, Tsai SJ, Chen YC. Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals. World J Clin Cases. 2019 Jun 6;7(11):1270-1281. doi: 10.12998/wjcc.v7.i11.1270. PMID: 31236391; PMCID: PMC6580345.
7. Khan MU, Mahmoud MI, Butt AA. Hepatitis c virus and chronic kidney disease. Expert Rev Gastroenterol Hepatol. 2020 Jul;14(7):579-590. doi: 10.1080/17474124.2020.1776111. Epub 2020 Jul 2. PMID: 32613874.
8. Juanbeltz R, Goñi Esarte S, Úriz-Otano JI, et al. Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions. Postgrad Med. 2017;129(4):476-83.
9. Perhimpunan Peneliti Hati Indonesia, Perhimpunan Nefrologi Indonesia. Penatalaksanaan Infeksi Hepatitis C pada PGK. 2019.
10. Perhimpunan Peneliti Hati Indonesia. Tatalaksana Hepatitis C. Konsensus Nasional Penatalaksanaan Hepatitis C di Indonesia, 2017.
11. Taneja S, Duseja A, De A, et al. Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease. Dig Dis Sci. 2018;63(5):1334-40.
12. Sperl J, Frankova S, Kreidlova M, Merta D, Tothova M, Spicak J. Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis. Ther Clin Risk Manag. 2017;13:733-8.
13. Goel A, Bhadauria DS, Kaul A, et al. Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min. Nephrology (Carlton). 2019;24(3):316-21.
14. Li M, Chen J, Fang Z, Li Y, Lin Q. Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4–5 chronic kidney disease: a systematic review and meta-analysis. Virology Journal. 2019;16(1):34.